Protopic

Protopic is a brand name of tacrolimus topical, approved by the FDA in the following formulation(s):

PROTOPIC (tacrolimus - ointment; topical)

• 
  Manufacturer: ASTELLAS
  
  Approval date: December 8, 2000
  
  Strength(s): 0.03%, 0.1% ^[RLD]

Has a generic version of Protopic been approved?

No. There is currently no therapeutically equivalent version of Protopic available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Protopic. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Ointments containing FK-506 or derivatives thereof
  Patent 5,385,907
  Issued: January 31, 1995
  Inventor(s): Asakura; Sotoo & Murakami; Yoshio & Kanagawa; Nobuto & Nakate; Toshiomi
  Assignee(s): Fujisawa Pharmaceutical Co., Ltd.
  An ointment comprising a tricyclic compound such as FK 506 substance which is 17-allyl-1,14-dihydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylviny l]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1 .0.sup.4,9 ]octacos-18-ene-2,3,10,16-tetraone, or the like, a solubilizing and/or absorption-promoting agent and an ointment base, which is useful for treating various skin diseases.
  
  Patent expiration dates:
  
  
  • January 31, 2012
    
    ✓ 
    Drug product
  
  



• 
  Use of 11,28-dioxa-4-azatricyclo›22.3.1.0.sup.4,9 !octacos-18-ene derivatives and pharmaceutical compositions containing them
  Patent 5,665,727
  Issued: September 9, 1997
  Inventor(s): Grassberger; Maximilian & Meingassner; Josef Gottfried & Stutz; Anton & Stutz; Peter
  Assignee(s): Sandoz Ltd.
  The compounds of formula I, ##STR1## have been found to have excellent topical activity. They are thus indicated for use in the topical treatment of inflammatory and hyperpoliferative skin diseases and of cutaneous manifestations of immunologically-induced illnesses, such as psoriasis.
  
  Patent expiration dates:
  
  
  • September 9, 2014
    
    ✓ 
    Patent use: FOR THE TREATMENT OF DERMATITIS
  
  

See also...

• Protopic Consumer Information (Drugs.com)
• Protopic Ointment Consumer Information (Wolters Kluwer)
• Protopic Consumer Information (Cerner Multum)
• Protopic Topical Advanced Consumer Information (Micromedex)
• Protopic topical AHFS DI Monographs (ASHP)
• Tacrolimus Ointment Consumer Information (Wolters Kluwer)
• Tacrolimus topical Consumer Information (Cerner Multum)
• Tacrolimus Topical Advanced Consumer Information (Micromedex)
• Tacrolimus topical AHFS DI Monographs (ASHP)